Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin

American Journal of Hematology

Volumn 87, Issue 8, 2012, Pages 833-836

  Shah, Anuja ^a   Molnar, Miklos Z ^b,c   Lukowsky, Lilia R ^b,d   Zaritsky, Joshua J ^e   Kovesdy, Csaba P ^f,g   Kalantar Zadeh, Kamyar ^a,b,d,e  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ADULT; ANEMIA; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY POLYCYSTIC DISEASE; LETTER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL;

AGED; COHORT STUDIES; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY DISEASES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 84864023110     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23255     Document Type: Letter

References (30)

1. Collins AJ, Li S, St. Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473.
2. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69: 560-564.
3. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changesin hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
4. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
5. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
6. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
7. Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010; 77: 239-246.
8. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the Untied States, Vol. 3. National Institute of Health, Bethesda, MD:National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2009.
9. Rizk D, Jurkovitz C, Veledar E, et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol 2009; 4: 560-566.
10. Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38: 777-784.
11. Abbott KC, Agodoa LY. Polycystic kidney disease in patients on the renal transplant waiting list: Trends in hematocrit and survival. BMC Nephrol 2002; 3: 7.
12. Milutinovic J, Fialkow PJ, Agodoa LY, et al. Autosomal dominant polycystic kidney disease: Symptoms and clinical findings. Q J Med 1984; 53: 511-522.
13. Gabow PA, Ikle DW, Holmes JH. Polycystic kidney disease: Prospective analysis of nonazotemic patients and family members. Ann Intern Med 1984; 101: 238-247.
14. Eckardt KU, Mollmann M, Neumann R, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989; 84: 1160-1166.
15. Ma JZ, Ebben J, Xia H, et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619.
16. Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011; 6: 1041-1048.
17. Goodkin DA, Fuller DS, Robinson BM, et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011; 22: 358-365.
18. Lankhorst CE, Wish JB. Anemia in renal disease: Diagnosis and management. Blood Rev 2010; 24: 39-47.
19. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010; 6: 699-710.
20. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31: 81-86.
21. Coyne DW. A comprehensive vision for intravenous iron therapy. Am J Kidney Dis 2008; 52: S14-S20.
22. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736.
23. Schwedler SB, Coresh J, Schinzel R. Advanced glycation end products and mortality in caring for ESRD. Kidney Int 2000; 11: 520-529.
24. Streja E, Kovesdy CP, Molnar MZ, et al. Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis 2011; 57: 883-893.
25. Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S, Streja E, Krishnan M, Kalantar-Zadeh K. Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int 2011; 80: 218-224.
26. Molnar MZ, Streja E, Kovesdy CP, Budoff MJ, Nissenson AR, Krishnan M, Anker SD, Norris KC, Fonarow GC, Kalantar-Zadeh K. High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. Am J Clin Nutr 2011; 94: 945-954.
27. Duong U, Kalantar-Zadeh K, Molnar MZ, et al. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol 2012; 35: 198-208.
28. Kalantar-Zadeh K, Streja E, Molnar MZ, et al. Mortality prediction by surrogates of body composition: An examination of the obesity paradox in hemodialysis patients using composite ranking score analysis. Am J Epidemiol, in press.
29. Ricks J, Molnar MZ, Kovesdy CP, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: A 6-year cohort study. Diabetes 2012; 61: 708-715.
30. Longenecker JC, Coresh J, Klag MJ, et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000; 11: 520-529.